Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis.
Fiche publication
Date publication
novembre 2021
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Amico F, Magro F, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Filgotinib is a small molecule that selectively inhibits Janus kinase (JAK) type 1. It is already approved for the treatment of rheumatoid arthritis and is being evaluated for the management of patients with moderate to severe ulcerative colitis (UC). The purpose of this review is to provide an overview of the currently available data on filgotinib and to define how to position this new drug in the treatment algorithm of patients with ulcerative colitis.
Mots clés
JAK inhibitor, filgotinib, inflammatory bowel disease, small molecule, ulcerative colitis
Référence
J Crohns Colitis. 2021 Nov 16;: